(Q34826429)

4 August 2017

1 reference

title

Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment (English)

1 reference

4 August 2017

0 references

1 reference

Richard A Rudick

1

1 reference

4 August 2017

Deborah M Miller

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

10

1 reference

4 August 2017

page(s)

827-839

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200822100-00004

4 August 2017

exact match

0 references

cites work

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Quality of life in multiple sclerosis: measuring the disease effects more broadly.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Validation of the functional assessment of multiple sclerosis quality of life instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200822100-00004

Does adding MS-specific items to a generic measure (the SF-36) improve measurement?

21 January 2018

1 reference

12 December 2020

Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis.

1 reference

12 December 2020

Measuring self-efficacy in people with multiple sclerosis: a validation study

1 reference

12 December 2020

Quality of life in multiple sclerosis: the disability and impact profile (DIP).

1 reference

12 December 2020

Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles

1 reference

12 December 2020

Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS).

1 reference

12 December 2020

Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a

1 reference

12 December 2020

Diagnosis and management of multiple sclerosis.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Psychometric assessment of the Quality of Life Index

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.

1 reference

12 December 2020

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

1 reference

12 December 2020

1 reference

12 December 2020

Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Developing a disease-specific quality of life measure for people with multiple sclerosis

1 reference

12 December 2020

Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review

1 reference

12 December 2020

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

1 reference

12 December 2020

Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group

1 reference

12 December 2020

Pathogenesis of multiple sclerosis

1 reference

12 December 2020

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

1 reference

12 December 2020

A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis.

1 reference

12 December 2020

Validation of the Multiple Sclerosis International Quality of Life questionnaire

1 reference

12 December 2020

Treatment with interferon beta-1b improves quality of life in multiple sclerosis.

1 reference

12 December 2020

Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life

1 reference

12 December 2020

A comparison of responsiveness indices in multiple sclerosis patients.

1 reference

12 December 2020

1 reference

12 December 2020

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

12 December 2020

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

12 December 2020

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

1 reference

12 December 2020

Quality of life in multiple sclerosis: development and validation of the 'RAYS' scale and comparison with the SF-36

1 reference

12 December 2020

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

12 December 2020

10.2165/00023210-200822100-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1007268642

0 references

1 reference